Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0047

Payer / HTA meeting · Dr. Chloé Rossi

16 Jan 2026 · Phone · Dr. Chloé Rossi, Universitätsklinikum Heidelberg · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0047—

Capture insight from this engagement

Location: Universitätsklinikum Heidelberg
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression

Scientific content used

PD-L1 testing pathway infographic
irAE management guide

Questions raised

No questions recorded.

Notes

Payer / HTA meeting with pathologist at Universitätsklinikum Heidelberg. Discussed sequencing after progression.

Insights captured (1)

Capture insight

INS-0070High
Sequencing after progression
Sequencing after progression: gap in current materials reported by pathologist (DE).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 1
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0047

Audit history (0)

All create, update and approval events for this record

No audit events in sample data